Drug delivery of oral anti-cancer fluoropyrimidine agents

Author:

Miura Koh1ORCID,Shima Hiroshi2,Takebe Naoko3,Rhie Julie4,Satoh Kennichi5,Kakugawa Yoichiro6,Satoh Masayuki1,Kinouchi Makoto1,Yamamoto Kuniharu1,Hasegawa Yasuhiro1,Kawai Masaaki6,Kanazawa Kousuke1,Fujiya Tsuneaki1,Unno Michiaki7,Katakura Ryuichi8

Affiliation:

1. Department of Surgery, Miyagi Cancer Center, Natori, Japan

2. Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan

3. Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA

4. Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Regulatory Affairs Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA

5. Miyagi Cancer Center Research Institute, Division of Cancer Stem Cell, Natori, Japan

6. Department of Breast Oncology, Miyagi Cancer Center, Natori, Japan

7. Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

8. Department of Neurosurgery, Miyagi Cancer Center, Natori, Japan

Funder

Osaka Basic Medical Research Foundation

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3